Ikeno Fumiaki, Ikeda Koji, Uchida Takahiro
Falk Cardiovascular Research Center, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5406, USA,
Cardiovasc Interv Ther. 2014 Jan;29(1):1-3. doi: 10.1007/s12928-013-0202-z. Epub 2013 Aug 23.
Patients' access to innovative medical devices in Japan still shows the gap between the other countries. The cause of this device gap is researched from the prior published data. We searched the review time of new innovative devices by the Pharmaceuticals and Medical Devices Agency (PMDA) and the submission time lag compared with the US and EU from the prior published data. The average review time was 9.5 months and the total time from PMDA to introduction of the device to patients in Japan is almost similar to the US and the four European countries. However, the time lag of the file submission between Japan and the US was 2.42 years, on average, between 2001 and 2009. The review time for new innovative medical devices by the PMDA has been improving year after year. On the contrary, the pre-submission delay still exists in Japan.
日本患者获取创新型医疗设备的情况与其他国家仍存在差距。我们根据先前发表的数据研究了造成这种设备差距的原因。我们从先前发表的数据中查找了药品和医疗器械管理局(PMDA)对新型创新设备的审评时间以及与美国和欧盟相比的提交时间滞后情况。平均审评时间为9.5个月,从PMDA到该设备在日本投入患者使用的总时间与美国和四个欧洲国家几乎相似。然而,2001年至2009年期间,日本和美国之间提交文件的时间滞后平均为2.42年。PMDA对新型创新医疗设备的审评时间逐年在改善。相反,日本仍存在提交前的延迟。